Skip to main content

Astria Therapeutics, Inc. (ATXS)

NASDAQ: ATXS · IEX Real-Time Price · USD
7.19
+0.16 (2.28%)
After-hours:Oct 15, 2021 7:14 PM EDT
7.03
-0.26 (-3.57%)
At close: Oct 15, 4:00 PM
Market Cap90.16M
Revenue (ttm)n/a
Net Income (ttm)-221.83M
Shares Out5.98M
EPS (ttm)-54.39
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume146,943
Open7.31
Previous Close7.29
Day's Range6.80 - 7.31
52-Week Range6.31 - 47.82
Beta1.70
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 11, 2021

About ATXS

Astria Therapeutics, Inc., a biopharmaceutical company, engages in developing therapies for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-021, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development stage for the treatment of hereditary angioedema, a rare genetic disorder causing swelling in the face, limbs, abdomen, and airway. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in Septe...

IndustryBiotechnology
IPO DateJun 25, 2015
Employees20
Stock ExchangeNASDAQ
Ticker SymbolATXS
Full Company Profile

Financial Performance

Financial Statements

News

Astria Therapeutics to Present Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD...

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced it will be presenting...

4 days ago - Business Wire

Astria Therapeutics to Present at Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that Jill C. Milne, P...

1 month ago - Business Wire

Catabasis Renames As Astria Therapeutics With New Disease Focus

Once-struggling, Catabasis Pharmaceuticals Inc (NASDAQ: CATB) is looking to hit the reset button with a new name and focus. Catabasis has been dragging for several years, weighed down mainly by the fail...

1 month ago - Benzinga

Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus

BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced its new name, A...

1 month ago - Business Wire

Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

2 months ago - Business Wire

Catabasis Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference

BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals To Present At 2021 Wedbush PacGrow Healthcare Conference

2 months ago - Business Wire

Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference

BOSTON--(BUSINESS WIRE)--Catabasis will present information on its lead program QLS-215 at the Ladenburg Thalmann 2021 Healthcare Conference.

3 months ago - Business Wire

Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today

Kindred Biosciences, Inc. (NASDAQ: KIN), Aprea Therapeutics, Inc. (NASDAQ: APRE), Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) and Inhibikase Therapeutics, Inc. (NASDAQ: IKT) are among the biggest bio...

Other symbols:APREIKT
4 months ago - Benzinga

Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences

5 months ago - Business Wire

Catabasis Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides a Corporate Update

BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides a Corporate Update

5 months ago - Business Wire

7 Penny Stocks That May Have Room to Run Higher

Investors in penny stocks know the prices of many have crashed. But these seven stocks may have room to run higher.

6 months ago - InvestorPlace

Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update

BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update

7 months ago - Business Wire

AEP, Oracle, Tesla and More Thursday Afternoon Analyst Calls

With the trading day halfway over, the broad markets were making yet another strong push.

7 months ago - 24/7 Wall Street

Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences.

7 months ago - Business Wire

CATB Stock: Why Catabasis Pharma Stock Is Skyrocketing Today

Catabasis Pharma (CATB) stock is soaring higher on Friday after announcing its acquisition of Quellis Biosciences and a PIPE. The post CATB Stock: Why Catabasis Pharma Stock Is Skyrocketing Today appear...

8 months ago - InvestorPlace

Implied Volatility Surging for Catabasis (CATB) Stock Options

Investors need to pay close attention to Catabasis (CATB) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

Catabasis Pharmaceuticals: 9 Things for Potential CATB Stock Investors to Know

Catabasis Pharmaceuticals (CATB) stock is taking off on Wednesday despite a lack of news from the biopharmaceutical company. The post Catabasis Pharmaceuticals: 9 Things for Potential CATB Stock Investo...

10 months ago - InvestorPlace

A Trio of Net Net Working Capital Stocks

There are some investors who buy stocks that are trading below their liquidation value because they believe they can make remarkable gains out of their investments after the market has reassessed the sh...

Other symbols:NVFY
10 months ago - GuruFocus

Catabasis Pharmaceuticals News: Why CATB Stock Is Plummeting 69% Today

Catabasis Pharmaceuticals (CATB) news for Tuesday includes incredibly poor results from a clinical trial hammering CATB stock hard. The post Catabasis Pharmaceuticals News: Why CATB Stock Is Plummeting ...

11 months ago - InvestorPlace

Catabasis Pharmaceuticals: Accumulating Ahead Of Edasalonexent's Top-Line Results

Catabasis is approaching its highly anticipated Q4 readout for their Phase III PolarisDMD study. If the data is acceptable, Catabasis expects to file an NDA in 2021.

1 year ago - Seeking Alpha

Are Options Traders Betting on a Big Move in Catabasis (CATB) Stock?

Investors need to pay close attention to Catabasis (CATB) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Catabasis Pharmaceuticals (CATB) Surges: Stock Moves 8.6% Higher

Catabasis Pharmaceuticals (CATB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

Catabasis: Worth A Look Ahead Of Phase III Data

Catabasis: Worth A Look Ahead Of Phase III Data

1 year ago - Seeking Alpha

Catabasis Pharmaceuticals Inc. (CATB) CEO Jill Milne on Q4 2019 Results - Earnings Call Transcript

Catabasis Pharmaceuticals Inc. (CATB) CEO Jill Milne on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Catabasis (CATB) Partners with UK-Based Charity for DMD Study

Catabasis (CATB) teams up with Duchenne UK to fund a phase II study of its pipeline candidate edasalonexent, now being developed to treat patients with non-ambulatory Duchenne muscular dystrophy.

1 year ago - Zacks Investment Research